Science to Market - S2M - is the platform for European scientific research and biopharmaceutical industry.
The goal of this European event is the promotion of collaborations between science and industry in the sector of pharmaceutical biotechnology to enhance the economical output of scientific research and direct them into marketable technologies and biopharmaceutical products.The conference is dedicated to innovative biopharmaceutical drug and diagnostic developments and novel technologies for the development and production of those products.
S2M 2011 will focus on "Challenges in the Development of Personalized Medicine". The paradigm change to personalized medicine is accompanied with basic changes in the pharma drug development process. This conference will discuss issues concerning alterations in the drug development process with special emphasis laying on the requirement of early-on-collaborations between drug companies and diagnostic manufacturers during development.
The summit offers plenary lectures on state-of-the-art technologies and findings in biopharmaceutical developments, poster presentations with speaking slots on current projects from academia and technology transfer as well as networking opportunities.
Poster presentations on scientific pharmaceutical drug projects and novel technologies in the fields of biotechnology and pharmaceutical drug development are welcome.
Partners of 2011's Science to Market are BioTOP and the European Biotechnology Network.BioTOP Berlin Brandenburg is the central contact and coordination office for all issues concerning biotechnology in the German capital region. EAPB and the European Biotechnology Network cooperate as partners in helping European biotechnology actors build successful technologies and businesses. Therefore day 2 of S2M offers an additional workshop about "Research funding for biotechnology companies in Europe. Funding opportunities from Europe and the US to support business and partnerships".
Kantstraße 8 (close by Bahnhof Zoo)